文献速递流行病学与生物统计真实世界研究与卫生经济

活体网状Meta分析与传统成对Meta分析在比较效果研究中的实证比较

Living network meta-analysis compared with pairwise meta-analysis in comparative effectiveness research: empirical study.
PubMed 文献 · BMJ · 2018-02-28

该实证研究纳入44个网状Meta分析中的49个临床关注的治疗比较,评估活体网状Meta分析是否比传统成对Meta分析更早提供反对零假设的强证据。结果显示,网状Meta分析在额外10个比较中提供强证据(P=0.002),中位时间19年 vs 23年(HR 2.78,95%CI 1.00-7.72,P=0.05)。

要点

  • 活体网状Meta分析较成对Meta分析更常且更早产生反对零假设的强证据。
  • 中位强证据时间:网状19年,成对23年(HR 2.78,95%CI 1.00-7.72)。
  • 网状Meta分析在额外10个比较中提供强证据(P=0.002)。

核心结论

  • 在比较效果研究中,前瞻性规划的活体网状Meta分析比传统成对Meta分析更常且更早产生反对零假设的强证据。

研究设计与样本

  • 实证研究,数据来源于截至2015年4月14日Medline、Embase和Cochrane系统评价数据库中的网状Meta分析。
  • 纳入2012年1月后发表、比较至少5种治疗且包含至少20项RCT的网状Meta分析,最终纳入44个网络的49个比较。

主要发现

  • 49个比较中多数(n=39,80%)为活性药物间比较,主要来自心脏病学、内分泌学、精神病学和风湿病学。
  • 29个比较(59%)由直接和间接证据支持,13个(27%)仅间接证据,7个(14%)仅直接证据。
  • 网状和成对Meta分析在7个比较中均提供强证据,但额外10个比较仅网状Meta分析提供强证据(P=0.002)。
  • 中位强证据时间:活体网状Meta分析19年,活体成对Meta分析23年(HR 2.78,95%CI 1.00-7.72,P=0.05)。
  • 在网状Meta分析已显示强证据后,仍有8个比较的直接比较研究继续发表。

关键数值与推荐

  • 直接与间接证据不一致(基于side或node splitting检验P<0.10)的比较被排除。
  • 监测边界设定显著性水平α=5%、把握度90%(β=10%),预期治疗效应等于网状Meta分析最终估计值。

临床怎么用

  • 在比较效果研究中,可考虑采用前瞻性规划的活体网状Meta分析以更早获得强证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine whether the continuous updating of networks of prospectively planned randomised controlled trials (RCTs) ("living" network meta-analysis) provides strong evidence against the null hypothesis in comparative effectiveness of medical interventions earlier than the updating of conventional, pairwise meta-analysis. DESIGN: Empirical study of the accumulating evidence about the comparative effectiveness of clinical interventions. DATA SOURCES: Database of network meta-analyses of RCTs identified through searches of Medline, Embase, and the Cochrane Database of Systematic Reviews until 14 April 2015. ELIGIBILITY CRITERIA FOR STUDY SELECTION: Network meta-analyses published after January 2012 that compared at least five treatments and included at least 20 RCTs. Clinical experts were asked to identify in each network the treatment comparison of greatest clinical interest. Comparisons were excluded for which direct and indirect evidence disagreed, based on side, or node, splitting test (P<0.10). OUTCOMES AND ANALYSIS: Cumulative pairwise and network meta-analyses were performed for each selected comparison. Monitoring boundaries of statistical significance were constructed and the evidence against the null hypothesis was considered to be strong when the monitoring boundaries were crossed. A significance level was defined as α=5%, power of 90% (β=10%), and an anticipated treatment effect to detect equal to the final estimate from the network meta-analysis. The frequency and time to strong evidence was compared against the null hypothesis between pairwise and network meta-analyses. RESULTS: 49 comparisons of interest from 44 networks were included; most (n=39, 80%) were between active drugs, mainly from the specialties of cardiology, endocrinology, psychiatry, and rheumatology. 29 comparisons were informed by both direct and indirect evidence (59%), 13 by indirect evidence (27%), and 7 by direct evidence (14%). Both network and pairwise meta-analysis provided strong evidence against the null hypothesis for seven comparisons, but for an additional 10 comparisons only network meta-analysis provided strong evidence against the null hypothesis (P=0.002). The median time to strong evidence against the null hypothesis was 19 years with living network meta-analysis and 23 years with living pairwise meta-analysis (hazard ratio 2.78, 95% confidence interval 1.00 to 7.72, P=0.05). Studies directly comparing the treatments of interest continued to be published for eight comparisons after strong evidence had become evident in network meta-analysis. CONCLUSIONS: In comparative effectiveness research, prospectively planned living network meta-analyses produced strong evidence against the null hypothesis more often and earlier than conventional, pairwise meta-analyses.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Nikolakopoulou A, Mavridis D, Furukawa TA, et al. Living network meta-analysis compared with pairwise meta-analysis in comparative effectiveness research: empirical study. BMJ. 2018. PMID: 29490922. doi:10.1136/bmj.k585

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。